[Artificial reconstituted pulmonary surfactant used for prevention and treatment of adult respiratory distress syndrome. III. Prevention in animal model].
Based on two major factors resulted in adult respiratory distress syndrome (ARDS), lack of pulmonary surfactant and damage of free radicals, an artificial reconstituted pulmonary surfactant (APS) was prepared. The results of prevention of ARDS in ARDS rats showed that APS reduced the mortality of animal model significantly (from 46.47% to 16.17%) and the ratio of wet/dry lung weight (from 5.55 to 4.84). The surface properties of lung lavage of treated animals were improved effectively [balancing surface tension from 61.86 mN.m-1 to 47.02 mN.m-1, (normal 43.94 mN.m-1), minimal surface tension from 30.41 mN.m-1 to 7.16 mN.m-1(normal 3.49 mN.m-1)]. These results indicate that the APS preparation showed better effect on prevention of ARDS in rats.
Division of Biopharmaceutics,  School of Pharmacy, Shanghai Medical University, Shanghai 200032.
Z Q
ZQ
Jiang
Y M
YM
Ma
N Z
NZ
Xi
D000818:Animals; D001992:Bronchoalveolar Lavage Fluid; D008070:Lipopolysaccharides; D008168:Lung / Q000473:pathology; D008297:Male; D011663:Pulmonary Surfactants / Q000627:therapeutic use*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use; D012128:Respiratory Distress Syndrome / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*
D008070:Lipopolysaccharides; D011663:Pulmonary Surfactants; D011994:Recombinant Proteins